Novavax Inc. ($NVAX) Stock Forecast: Down 7.4% Today

What is Novavax Inc.?

Novavax, Inc. (NVAX) is a biotechnology company specializing in innovative vaccines for infectious diseases, with a focus on COVID-19 vaccine research and clinical trials.

Why is Novavax Inc. going down?

NVAX stock is down 7.4% on Jun 8, 2026 19:00

• Despite recent positive sentiment, Novavax (NVAX) saw a significant 6.87% drop in its shares, performing below market expectations.
• The decline may be linked to profit-taking following a 10.4% surge post-earnings report, prompting investors to review their holdings.
• While early COVID-19 vaccine trials and analyst enthusiasm initially drove the stock up, market realities and profit concerns likely led to the recent downturn.
• Investors are advised to keep an eye on forthcoming clinical trial outcomes and market conditions for a clearer picture of the stock's future trajectory.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) has recently garnered significant investor interest, leading to its status as one of Zacks.com's most-searched stocks. Despite recent stock dips, fundamental analysis through earnings estimate revisions and revenue growth forecasts suggests the company holds a Zacks Rank #3 (Hold), indicating expected performance in line with the broader market. Investors are encouraged to consider these factors, along with valuation metrics, for informed decision-making regarding NVAX.

https://sg.finance.yahoo.com/news/novavax-inc-nvax-attracting-investor-130005087.html

Novavax (NVAX) up 10.4% since last earnings report: Can it continue?

This article discusses Novavax's stock performance, noting a 10.4% increase since its last earnings report. It poses the question of whether this upward trend can be sustained. The full article content was not provided, so a detailed summary of its arguments is not possible.

https://www.msn.com/en-us/money/topstocks/novavax-nvax-up-10-4-since-last-earnings-report-can-it-continue/ar-AA24VNlR

NVAX Financials: Revenue Breakdown, Margins & Competitor Comparison

This article analyzes Novavax Inc.'s (NVAX) financial performance, focusing on its revenue breakdown, profitability margins, and competitive positioning within the Biotechnology & Medical Research industry. It highlights that Licensing Royalties And Other is NVAX's largest revenue contributor, and compares its gross margin to competitors ANIP and QURE. The analysis provides key insights into NVAX's operational efficiency and market standing.

https://intellectia.ai/en/stock/NVAX/financials

Novavax Inc. stock underperforms Friday when compared to competitors

Novavax Inc. (NVAX) shares fell 6.87% on Friday, closing at $9.49, significantly underperforming the broader market indices, including the NASDAQ Composite and the Dow Jones Industrial Average. This marks the fifth consecutive day of losses for the stock.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-friday-when-compared-to-competitors-6529b689-27f552158041?mod=mw_quote_news

Novavax, Inc. Trade Ideas — BSESOF:NVV1

This article compiles various trade ideas and technical analyses for Novavax, Inc. (NVV1/NVAX) from different traders on TradingView. The prevailing sentiment is bullish, driven by the potential for a "3 wave" extensive rally, ongoing COVID-19 vaccine trials, and technical indicators such as Fibonacci retracements and wedge formations. Many analysts highlight the company's strong fundamentals in the pharmaceutical sector and anticipate significant price movements pending positive clinical trial results.

https://www.tradingview.com/symbols/BSESOF-NVV1/ideas/page-15/

Trending Today

Whirlpool Corporation ($WHR) Stock Forecast: Up 5.1% Today

Mohawk Industries Inc. ($MHK) Stock Forecast: Up 5.3% Today

Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Up 5.1% Today

Southwest Airlines Company ($LUV) Stock Forecast: Up 5.1% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.7% Today

First Solar Inc. ($FSLR) Stock Forecast: Down 5.6% Today

Penn National Gaming Inc. ($PENN) Stock Forecast: Up 5.3% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 8.1% Today

Pool Corporation ($POOL) Stock Forecast: Up 6.9% Today

Alexandria Real Estate Equities Inc. ($ARE) Stock Forecast: Up 5.3% Today

Novavax Inc. Price History

28.04.2026 - NVAX Stock was down 9.9%

• Despite recent insider selling by Ruxandra Draghia Akli, Novavax Inc. experienced a strong bearish movement today.
• The stock had been performing well in the past few days, outperforming competitors and showing consecutive gains.
• However, the stock closed significantly below its 52-week high, indicating some profit-taking by investors.
• The mixed trading day in the market, along with profit-taking and potential concerns about insider selling, might have contributed to the bearish movement in Novavax's stock price today.

26.04.2026 - NVAX Stock was up 6.3%

• Novavax Inc. (NVAX) stock outperformed its competitors and major indices like the NASDAQ Composite and Dow Jones Industrial Average, showcasing resilience and strength in its market position.
• The fluctuation in Novavax's stock price can be attributed to its operating margin percentage, indicating potential financial health and operational efficiency improvements.
• Despite a recent decline, Novavax bounced back with a 4.16% increase, breaking a losing streak and demonstrating investor confidence in the company's future prospects.
• Overall, Novavax's stock movement today reflects both internal financial metrics and broader market trends, positioning the company as a key player in the biotechnology sector with promising growth potential.

29.04.2026 - NVAX Stock was up 5.4%

• Despite a favorable market environment yesterday, Novavax Inc. lagged behind its competitors, possibly due to profit-taking following a recent winning streak.
• The sale of 30,000 NVAX shares by an insider initially sparked some market uncertainty, but its overall impact was neutral, indicating a limited influence on the stock's upward trend.
• Novavax's consistent gains and outperformance relative to its peers reflect positive market sentiment and strong trading sessions driving the surge in the stock.
• While not directly linked to stock movement, Novavax's operating margin percentage in financial data may offer insights into the company's financial well-being and future growth prospects. This factor enhances investor confidence and bolsters the bullish momentum.

05.05.2026 - NVAX Stock was down 5.7%

• Novavax Inc. (NVAX) saw a decline in its stock price for the second day in a row, despite overall market gains.
• Investor worries may have been exacerbated by a looming deadline in a legal case accusing the company of making misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline.
• Participation in a healthcare conference did not have a positive impact on Novavax's stock performance.
• The stock's lag behind competitors and its 52-week high have contributed to the prevailing negative investor sentiment towards Novavax Inc., causing a downward trend in the market.

08.05.2026 - NVAX Stock was down 7.4%

• Despite recent positive sentiment, Novavax (NVAX) saw a significant 6.87% drop in its shares, performing below market expectations.
• The decline may be linked to profit-taking following a 10.4% surge post-earnings report, prompting investors to review their holdings.
• While early COVID-19 vaccine trials and analyst enthusiasm initially drove the stock up, market realities and profit concerns likely led to the recent downturn.
• Investors are advised to keep an eye on forthcoming clinical trial outcomes and market conditions for a clearer picture of the stock's future trajectory.

08.05.2026 - NVAX Stock was down 5.3%

• The bearish movement in NVAX's stock price can be attributed to a combination of factors:
• The underperformance compared to competitors and broader market indices on multiple consecutive days indicates a lack of investor confidence in the company's current financial performance and growth prospects.
• The looming deadline for investors to file in a securities class action lawsuit alleging misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline could be adding further downward pressure on the stock.
• Despite bullish sentiments from some traders based on technical analysis and ongoing vaccine trials, the negative news surrounding the lawsuit and consistent stock underperformance seem to be overshadowing any positive momentum.
• Overall, the market sentiment towards NVAX appears cautious and uncertain, with investors closely monitoring both the company's financial results and legal developments.

13.04.2026 - NVAX Stock was down 5.2%

• Following positive updates like collaborations with Pfizer and Sanofi, Novavax (NVAX) saw a rise in stock value but observed a downward trend in the current trading session.
• The company's weaker market performance compared to its competitors hints at a potential shift in investor sentiment, leading to profit-taking activities or concerns about its future growth.
• Mixed signals from technical indicators signaling a strong buy stance while options data suggests a preference for downside protection, indicating uncertainty surrounding NVAX's future direction.
• Despite recent positive developments propelling Novavax forward as a growth-oriented player in the vaccine industry, persistent challenges related to profitability and debt likely contributed to today's negative market movement.

27.04.2026 - NVAX Stock was up 10.2%

• NVAX stock surged by 13.57% to $10.46, marking the second consecutive day of gains, showcasing strong investor confidence in the company's future prospects.
• The positive market movement could be attributed to the company's promising vaccine development pipeline and potential breakthroughs in the fight against infectious diseases.
• Despite fluctuations in the broader market, NVAX's consistent outperformance indicates a favorable sentiment towards the company's innovative approach and growth potential.
• Investors seem optimistic about NVAX's ability to capitalize on the increasing demand for vaccines, driving the stock price higher amidst a volatile market environment.

20.04.2026 - NVAX Stock was up 5.3%

• NVAX stock has recently lagged behind its competitors, but today's positive movement suggests a potential shift in investor sentiment.
• Analysis indicates a temporary negative sentiment with a positive long-term projection, signaling investors' focus on broader factors beyond short-term fluctuations.
• Novavax's emphasis on entering seasonal booster markets and expanding its vaccine offerings may contribute to the optimistic investor sentiment and the stock's recent upswing.
• Updates on Novavax's advancements in COVID-19 vaccine development and strategic initiatives post-pandemic are likely factors driving confidence in the company's future, reflected in today's positive market performance.

02.05.2026 - NVAX Stock was down 6.2%

• Novavax recently took part in the 2026 Jefferies Global Healthcare Conference to showcase its vaccine technology platform. However, this did not translate into a positive market response for the stock.
• Despite a generally favorable trading day for the broader market, Novavax's stock performed worse than its competitors, closing 4.19% lower.
• AI-driven liquidity mapping analysis for NVAX suggested strong sentiment and potential upside, yet the stock still faced a bearish trend.
• The stock closed below its 52-week high, signaling potential investor concerns about the company's growth prospects or market conditions, contributing to the bearish movement.

02.05.2026 - NVAX Stock was down 5.1%

• NVAX stock experienced a downtrend today, potentially due to the approaching deadline for investors to join a securities class action lawsuit. This lawsuit alleges misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline, resulting in significant financial setbacks.
• Despite participation in a recent conference to discuss its vaccine technology platform, the negative impact of the pending lawsuit appears to have overshadowed any positive developments for the company.
• NVAX stock's underperformance relative to its peers, despite overall positive market conditions, indicates that investor sentiment may be more influenced by legal uncertainties than company-specific news or market trends.
• The stock showed some improvement on a strong trading day, surpassing the broader market. However, it still closed below its 52-week high, suggesting ongoing concerns related to the lawsuit are impacting investor confidence in Novavax's future prospects.

14.04.2026 - NVAX Stock was down 5.0%

• NVAX stock closed at $9.23, showing a bearish movement of 4.05% today.
• Despite recent positive news related to partnerships and earnings, NVAX underperformed its competitors and the broader market.
• The mixed trading session and market sentiment likely played a role in the bearish movement of NVAX stock.
• Investors, especially the "smart money," exhibit caution towards the stock's long-term prospects. Technical indicators lean towards a strong buy, while options data signal a preference for downside protection.